GlycoMimetics Sale Purchase Of Stock vs Capital Expenditures Analysis

GLYC Stock

USD 0.32 0.03 10.34%

GlycoMimetics financial indicator trend analysis is much more than just examining GlycoMimetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GlycoMimetics is a good investment. Please check the relationship between GlycoMimetics Sale Purchase Of Stock and its Capital Expenditures accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.

Sale Purchase Of Stock vs Capital Expenditures

Sale Purchase Of Stock vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GlycoMimetics Sale Purchase Of Stock account and Capital Expenditures. At this time, the significance of the direction appears to have almost no relationship.

The correlation between GlycoMimetics' Sale Purchase Of Stock and Capital Expenditures is 0.1. Overlapping area represents the amount of variation of Sale Purchase Of Stock that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of GlycoMimetics, assuming nothing else is changed. The correlation between historical values of GlycoMimetics' Sale Purchase Of Stock and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Sale Purchase Of Stock of GlycoMimetics are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Sale Purchase Of Stock i.e., GlycoMimetics' Sale Purchase Of Stock and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.1

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Sale Purchase Of Stock

Capital Expenditures

Capital Expenditures are funds used by GlycoMimetics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of GlycoMimetics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from GlycoMimetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlycoMimetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 2,017, whereas Selling General Administrative is forecasted to decline to about 13.3 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	264.6K	207.1K	175.7K	198.4K
Interest Income	19.8K	714.5K	2.2M	1.3M

Reconciled Depreciation Interest Income

GlycoMimetics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Net Tangible Assets
Total Assets		0.66	0.18	0.98	-0.26	0.66	-0.32	-0.98	-0.33	0.79	0.98	0.74	0.63	0.03	0.98	0.59	0.55	0.03	0.41	0.63	0.16	0.46	1.0	0.56	0.37	0.94
Other Current Liab	0.66		0.04	0.65	-0.58	0.74	-0.59	-0.63	-0.63	0.51	0.63	0.8	0.62	0.18	0.63	0.79	0.81	-0.16	0.33	0.78	-0.03	0.75	0.65	0.79	0.6	0.44
Total Current Liabilities	0.18	0.04		0.09	0.75	0.2	0.75	-0.18	-0.06	-0.06	0.18	0.25	0.08	0.37	0.18	-0.02	0.0	0.86	0.12	0.08	0.99	0.21	0.18	-0.04	-0.09	0.15
Total Stockholder Equity	0.98	0.65	0.09		-0.31	0.64	-0.36	-1.0	-0.26	0.79	1.0	0.71	0.61	0.02	1.0	0.54	0.55	-0.01	0.41	0.62	0.07	0.47	0.98	0.56	0.38	0.96
Other Liab	-0.26	-0.58	0.75	-0.31		-0.36	0.99	0.23	0.42	-0.36	-0.23	-0.35	-0.4	0.13	-0.23	-0.56	-0.51	0.8	-0.12	-0.45	0.79	-0.35	-0.26	-0.54	-0.45	-0.16
Property Plant And Equipment Net	0.66	0.74	0.2	0.64	-0.36		-0.36	-0.62	-0.47	0.47	0.63	0.95	0.68	0.12	0.63	0.59	0.57	0.19	0.72	0.63	0.21	0.8	0.65	0.57	0.38	0.57
Current Deferred Revenue	-0.32	-0.59	0.75	-0.36	0.99	-0.36		0.28	0.42	-0.45	-0.28	-0.35	-0.39	0.14	-0.28	-0.59	-0.53	0.81	-0.1	-0.47	0.79	-0.33	-0.32	-0.57	-0.51	-0.2
Net Debt	-0.98	-0.63	-0.18	-1.0	0.23	-0.62	0.28		0.23	-0.78	-1.0	-0.7	-0.6	-0.05	-1.0	-0.51	-0.52	-0.06	-0.39	-0.6	-0.15	-0.45	-0.98	-0.53	-0.35	-0.96
Retained Earnings	-0.33	-0.63	-0.06	-0.26	0.42	-0.47	0.42	0.23		-0.3	-0.23	-0.49	-0.37	-0.18	-0.23	-0.93	-0.89	0.16	-0.09	-0.89	0.01	-0.59	-0.32	-0.89	-0.66	-0.12
Accounts Payable	0.79	0.51	-0.06	0.79	-0.36	0.47	-0.45	-0.78	-0.3		0.77	0.55	0.55	0.24	0.77	0.53	0.46	-0.24	0.03	0.53	-0.09	0.39	0.79	0.5	0.6	0.74
Cash	0.98	0.63	0.18	1.0	-0.23	0.63	-0.28	-1.0	-0.23	0.77		0.71	0.6	0.05	1.0	0.51	0.52	0.07	0.4	0.6	0.16	0.47	0.98	0.53	0.35	0.96
Non Current Assets Total	0.74	0.8	0.25	0.71	-0.35	0.95	-0.35	-0.7	-0.49	0.55	0.71		0.84	0.27	0.71	0.64	0.63	0.12	0.61	0.68	0.24	0.79	0.72	0.62	0.49	0.63
Non Currrent Assets Other	0.63	0.62	0.08	0.61	-0.4	0.68	-0.39	-0.6	-0.37	0.55	0.6	0.84		0.43	0.6	0.5	0.48	-0.14	0.33	0.53	0.06	0.58	0.62	0.47	0.52	0.57
Other Assets	0.03	0.18	0.37	0.02	0.13	0.12	0.14	-0.05	-0.18	0.24	0.05	0.27	0.43		0.05	0.1	0.17	0.12	-0.11	0.19	0.32	0.46	0.02	0.15	0.61	0.01
Cash And Short Term Investments	0.98	0.63	0.18	1.0	-0.23	0.63	-0.28	-1.0	-0.23	0.77	1.0	0.71	0.6	0.05		0.51	0.52	0.07	0.4	0.6	0.16	0.47	0.98	0.53	0.35	0.96
Common Stock Total Equity	0.59	0.79	-0.02	0.54	-0.56	0.59	-0.59	-0.51	-0.93	0.53	0.51	0.64	0.5	0.1	0.51		0.94	-0.28	0.17	0.93	-0.09	0.6	0.59	0.95	0.71	0.37
Common Stock Shares Outstanding	0.55	0.81	0.0	0.55	-0.51	0.57	-0.53	-0.52	-0.89	0.46	0.52	0.63	0.48	0.17	0.52	0.94		-0.19	0.2	0.98	-0.08	0.68	0.54	0.99	0.74	0.37
Non Current Liabilities Total	0.03	-0.16	0.86	-0.01	0.8	0.19	0.81	-0.06	0.16	-0.24	0.07	0.12	-0.14	0.12	0.07	-0.28	-0.19		0.31	-0.09	0.9	0.19	0.02	-0.23	-0.34	0.1
Other Current Assets	0.41	0.33	0.12	0.41	-0.12	0.72	-0.1	-0.39	-0.09	0.03	0.4	0.61	0.33	-0.11	0.4	0.17	0.2	0.31		0.25	0.18	0.47	0.4	0.18	0.02	0.42
Other Stockholder Equity	0.63	0.78	0.08	0.62	-0.45	0.63	-0.47	-0.6	-0.89	0.53	0.6	0.68	0.53	0.19	0.6	0.93	0.98	-0.09	0.25		0.01	0.73	0.62	0.98	0.71	0.49
Total Liab	0.16	-0.03	0.99	0.07	0.79	0.21	0.79	-0.15	0.01	-0.09	0.16	0.24	0.06	0.32	0.16	-0.09	-0.08	0.9	0.18	0.01		0.17	0.15	-0.11	-0.17	0.15
Property Plant And Equipment Gross	0.46	0.75	0.21	0.47	-0.35	0.8	-0.33	-0.45	-0.59	0.39	0.47	0.79	0.58	0.46	0.47	0.6	0.68	0.19	0.47	0.73	0.17		0.45	0.67	0.63	0.36
Total Current Assets	1.0	0.65	0.18	0.98	-0.26	0.65	-0.32	-0.98	-0.32	0.79	0.98	0.72	0.62	0.02	0.98	0.59	0.54	0.02	0.4	0.62	0.15	0.45		0.55	0.37	0.94
Common Stock	0.56	0.79	-0.04	0.56	-0.54	0.57	-0.57	-0.53	-0.89	0.5	0.53	0.62	0.47	0.15	0.53	0.95	0.99	-0.23	0.18	0.98	-0.11	0.67	0.55		0.75	0.39
Property Plant Equipment	0.37	0.6	-0.09	0.38	-0.45	0.38	-0.51	-0.35	-0.66	0.6	0.35	0.49	0.52	0.61	0.35	0.71	0.74	-0.34	0.02	0.71	-0.17	0.63	0.37	0.75		0.22
Net Tangible Assets	0.94	0.44	0.15	0.96	-0.16	0.57	-0.2	-0.96	-0.12	0.74	0.96	0.63	0.57	0.01	0.96	0.37	0.37	0.1	0.42	0.49	0.15	0.36	0.94	0.39	0.22

Click cells to compare fundamentals

GlycoMimetics Account Relationship Matchups

GlycoMimetics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	168.0M	142.8M	94.3M	51.8M	45.3M	88.5M
Other Current Liab	8.7M	9.4M	8.7M	7.0M	5.2M	6.0M
Total Current Liabilities	11.0M	12.4M	11.8M	8.9M	6.8M	9.5M
Total Stockholder Equity	154.2M	128.2M	81.6M	42.9M	38.4M	36.5M
Property Plant And Equipment Net	3.8M	2.9M	1.9M	993.6K	767.8K	1.3M
Net Debt	(154.6M)	(134.2M)	(88.3M)	(47.0M)	(41.0M)	(43.0M)
Retained Earnings	(258.4M)	(309.5M)	(372.9M)	(419.6M)	(456.5M)	(433.7M)
Accounts Payable	1.4M	2.1M	2.1M	970.2K	868.1K	1.5M
Cash	158.2M	137.0M	90.3M	47.9M	41.8M	39.7M
Non Current Assets Total	5.4M	4.6M	4.1M	1.1M	1.5M	2.2M
Other Assets	321.0	(169.0)	1.6M	411.0	1.0	0.95
Cash And Short Term Investments	158.2M	137.0M	90.3M	47.9M	41.8M	39.7M
Common Stock Total Equity	34.4K	43.2K	43.5K	49.0K	56.4K	59.2K
Common Stock Shares Outstanding	43.3M	45.7M	51.5M	52.5M	63.3M	32.9M
Liabilities And Stockholders Equity	168.0M	142.8M	94.3M	51.8M	45.3M	88.5M
Non Current Liabilities Total	2.8M	2.2M	918.6K	1.9M	66.8K	63.5K
Other Current Assets	4.3B	1.2M	532.5K	2.7M	1.8M	1.7M
Other Stockholder Equity	412.6M	437.6M	454.4M	462.5M	494.8M	300.5M
Total Liab	13.8M	14.6M	12.7M	8.9M	6.9M	10.6M
Property Plant And Equipment Gross	3.8M	2.9M	4.3M	3.4M	767.8K	729.4K
Total Current Assets	162.5M	138.3M	90.3M	50.7M	43.8M	86.3M
Common Stock	43.5K	49.0K	52.3K	54.4K	64.4K	35.1K
Property Plant Equipment	822.9K	620.7K	1.9M	993.6K	1.1M	876.5K
Net Tangible Assets	154.2M	128.2M	81.6M	42.9M	49.4M	46.9M
Net Receivables	186.0K	2.1K	1.3K	144.0K	175.8K	148.9K
Retained Earnings Total Equity	(152.3M)	(200.6M)	(258.4M)	(309.5M)	(278.5M)	(264.6M)
Capital Surpluse	271.9M	406.0M	412.6M	437.6M	503.3M	304.1M
Inventory	(4.3B)	(1.2B)	(533.8M)	(144.4K)	(130.0K)	(136.5K)
Net Invested Capital	154.2M	128.2M	81.6M	42.9M	38.4M	36.5M
Net Working Capital	151.6M	125.8M	79.0M	41.8M	37.0M	35.1M
Capital Stock	43.5K	49.0K	52.3K	54.4K	64.4K	56.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether GlycoMimetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of GlycoMimetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Glycomimetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Glycomimetics Stock:

How To Invest In GlycoMimetics

Details

Is GlycoMimetics Stock a good investment?

Details

What is GlycoMimetics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.62)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.59)

Return On Equity

(1.04)

The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GlycoMimetics Sale Purchase Of Stock vs Capital Expenditures Analysis

Sale Purchase Of Stock vs Capital Expenditures

Sale Purchase Of Stock vs Capital Expenditures Correlation Analysis

Correlation Coefficient

Sale Purchase Of Stock

Capital Expenditures

GlycoMimetics fundamental ratios Correlations

GlycoMimetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GlycoMimetics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Total Current Liabilities
Current Deferred Revenue	+ 0.99	Other Liab

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.98	Total Assets
Net Tangible Assets	- 0.96	Net Debt